# US 2014/0234961 A1 · SYNTHETIC SINGLE CHAIN VARIABLE DOMAIN (SCFV) IMMUNOGLOBULIN FRAGMENT VEHICLE CONTAINING FUSION PROTEINS FOR TARGETED INTRODUCTION OF siRNA

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0234961 A1
- Document ID: US20140234961A1
- Status: Published application
- Kind: A1
- Application number: 14/072,500
- Filed: 2013-11-05
- Published: 2014-08-21
- Earliest claimed: 2012-11-05
- Inventors: Michael R. Simon; Reginald Michael Garavito
- Web page: https://patentgrep.com/patent/US20140234961A1

## CPC

- A61K 47/6807: {the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense}
- A61K 47/6811: {the drug being a protein or peptide, e.g. transferrin or bleomycin}
- A61K 47/6849: {the antibody targeting a receptor, a cell surface antigen or a cell surface determinant}
- A61K 47/6851: {the antibody targeting a determinant of a tumour cell}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A fusion protein and process are provided by which double-stranded RNA containing small interfering RNA nucleotide sequences is introduced into specific cells and tissues. A cell surface receptor specific synthetic single chain variable domain (scFv) immunoglobulin fragment vehicle specific to a cell surface receptor of the cell and having a cell surface receptor specific binding site is provided. An RNA binding protein fused to said scFv is adsorbed with a double-stranded RNA or to a small hairpin RNA sequence complementary to a nucleotide sequence of a target gene in the cell and includes a small interfering RNA operative to suppress production of a target cellular protein. The scFv induces internalization into said cell of the fusion protein subsequent to the binding of said scFV to the cell surface receptor of the target cell.

## Claims

### Claim 1

A fusion protein comprising:
a cell surface receptor specific synthetic single chain variable domain (scFv) immunoglobulin fragment vehicle specific to a cell surface receptor of a cell and having a cell surface receptor specific binding site;
an RNA binding protein fused to said scFv; and
a double-stranded RNA or to a small hairpin RNA sequence complementary to a nucleotide sequence of a target gene in the cell and comprising a small interfering RNA operative to suppress production of a cellular protein, said double-stranded RNA or said small hairpin RNA sequence adsorbing said RNA binding protein;
said scFv induces internalization into said cell of the fusion protein subsequent to the binding of said scFV to the cell surface receptor of the target cell.

### Claim 2 (depends on 1)

The fusion protein of claim 1 wherein said RNA binding protein is selected from the group consisting of: histone, protamine, cysteine-less human protamine 1 fused with the heavy chain of human ferritin, RDE4 and PKR (Accession number in parenthesis) (AAA36409, AAA61926, Q03963), TRBP (P97473, AAA36765), PACT (AAC25672, AAA49947, NP—609646), Staufen (AAD17531, AAF98119, AAD17529, P25159), NFAR1 (AF167569), NFAR2 (AF167570, AAF31446, AAC71052, AAA19960, AAA19961, AAG22859), SPNR (AAK20832, AAF59924, A57284), RHA (CAA71668, AAC05725, AAF57297), NREBP (AAK07692, AAF23120, AAF54409, T33856), kanadaptin (AAK29177, AAB88191, AAF55582, NP—499172, NP—198700, BAB19354), HYL1 (NP—563850), hyponastic leaves (CAC05659, BAB00641), ADAR1 (AAB97118, P55266, AAK16102, AAB51687, AF051275), ADAR2 P78563, P51400, AAK17102, AAF63702), ADAR3 (AAF78094, AAB41862, AAF76894), TENR (XP—059592, CAA59168), RNaseIII (AAF80558, AAF59169, Z81070Q02555/S55784, P05797), and Dicer (BAA78691, AF408401, AAF56056, S44849, AAF03534, Q9884), RDE-4 (AY071926), F1120399 (NP—060273, BAB26260), CG1434 (AAF48360, EAA12065, CAA21662), CG13139 (XP—059208, XP—143416, XP—110450, AAF52926, EEA14824), DGCRK6 (BAB83032, XP—110167) CG1800 (AAF57175, EAA08039), F1120036 (AAH22270, XP—134159), MRP-L45 (BAB14234, XP—129893), CG2109 (AAF52025), CG12493 (NP—647927), CG10630 (AAF50777), CG17686 (AAD50502), T22A3.5 (CAB03384) and nameless Accession number EAA14308.

### Claim 3 (depends on 1)

The fusion protein of claim 1 wherein said scFv is monomeric.

### Claim 4 (depends on 1)

The fusion protein of claim 1 wherein said scFv is tetravalent.

### Claim 5 (depends on 1)

The fusion protein of claim 1 wherein said scFv is polyvalent.

### Claim 6 (depends on 1)

The fusion protein of claim 1 wherein said double-stranded RNA is complementary to a cellular nucleotide sequence for a cell binding said ligand.

### Claim 7 (depends on 1)

The fusion protein of claim 1 wherein the ligand and RNA binding protein are conjugated in vitro.

### Claim 8 (depends on 1)

The fusion protein of claim 1 further comprising an internalization moiety having a bond to said scFv.

### Claim 9 (depends on 1)

The fusion protein of claim 1 wherein said internalization moiety has a bond to said RNA binding protein.

### Claim 10 (depends on 9)

The fusion protein of claim 9 wherein said internalization moiety is selected from the group of membrane-permeable arginine-rich peptides, pentratin, transportan, and transportan deletion analogs.

### Claim 11 (depends on 1)

The fusion protein of claim 1 wherein said scFv is an anti-CD177 synthetic single chain variable domain (scFv) immunoglobulin fragment vehicle and said double-stranded RNA is complementary to a portion of a malignant cell genome.

### Claim 12 (depends on 1)

The fusion protein of claim 1 wherein said small interfering RNA sequence is complementary to a JAK2 sequence.

### Claim 13 (depends on 1)

The fusion protein of claim 1 wherein said scFv is an anti-CD177 synthetic single chain variable domain (scFv) immunoglobulin fragment vehicle and said double-stranded RNA is coding for an anti-JAK2 small interfering RNA.

### Claim 14 (depends on 13)

The protein of claim 13 wherein said internalization moiety is selected from the group of membrane-permeable arginine-rich peptides, pentratin, transportan, and transportan deletion analogs.

### Claim 15 (depends on 1)

The fusion protein of claim 1 wherein said RNA binding protein is free of cysteine residues.

### Claim 16 (depends on 1)

The fusion protein of claim 1 having an amino acid sequence of one of SEQ ID NO 10, 12, or 15.

### Claim 17 (depends on 1)

The fusion protein of claim 1 having an amino acid sequence of one of SEQ ID NO 18, 21, or 23.

### Claim 18 (depends on 1)

A process for suppressing cellular production of a protein comprising: exposing a cell having a cell surface receptor to the fusion protein of claim 1.
